# Publications

## Peer-reviewed journal articles

[**Blankart KE**, Stargardt T. The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics. 2020;29(S1):63–82.](https://doi.org/10.1002/hec.4108) 

[**Blankart KE**, Lichtenberg FR. Are patients more adherent to newer drugs? Health Care Manag Sci. 2020 Aug 8;23:605–18.](https://doi.org/10.1007/s10729-020-09513-5)

[**Blankart KE**, Arndt F. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. International Journal of Environmental Research and Public Health. 2020 Jan;17(11):4113.](https://www.mdpi.com/1660-4601/17/11/4113)

[Winter V, Thomsen MK, Schreyögg J, **Blankart K**, Duminy L, Schoenenberger L, et al. Improving Service Provision - The Health Care Services’ Perspective. SMR. 2019;3(4):163–83.](https://elibrary.vahlen.de/index.php?doi=10.15358/2511-8676-2019-4-163)


[Guhl D, **Blankart KE**, Stargardt T. Service quality and perceived customer value in community pharmacies. Health Services Management Research. 2019 Feb 1;32(1):36–48.](http://journals.sagepub.com/doi/10.1177/0951484818761730)

[**Fischer KE**, Koch T, Kostev K, Stargardt T. The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ. 2018 Mar 1;19(2):213–22.](https://link.springer.com/article/10.1007/s10198-017-0875-9)

[Hostenkamp G, **Fischer KE**, Borch-Johnsen K. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health Policy. 2016;120(12):1404–11.](http://www.sciencedirect.com/science/article/pii/S0168851016302664)

[Guhl D, Stargardt T, Schneider U, **Fischer KE**. Dispensing behaviour of pharmacies in prescription drug markets. Health Policy. 2016 Feb;120(2):190–7.](http://www.sciencedirect.com/science/article/pii/S0168851016000245)

[**Fischer KE**, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016 Nov 1;17(8):1027–40.](http://link.springer.com/article/10.1007/s10198-015-0744-3)

[**Fischer KE**, Heisser T, Stargardt T. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. Health Policy. 2016 Oct;120(10):1115–22.](http://www.sciencedirect.com/science/article/pii/S0168851016302044)

[**Fischer KE**, Stargardt T. Early Benefit Assessment of Pharmaceuticals in Germany Manufacturers’ Expectations versus the Federal Joint Committee’s Decisions. Med Decis Making. 2014 Nov 1;34(8):1030–47.](http://mdm.sagepub.com/content/34/8/1030)

[**Fischer KE**, Rogowski WH. Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. International Journal of Environmental Research and Public Health. 2014 May 19;11(5):5403–30.](http://www.mdpi.com/1660-4601/11/5/5403)

[**Fischer KE**, Leidl R. Analysing coverage decision-making: opening Pandora’s box? Eur J Health Econ. 2014;15(9):889–906.](http://link.springer.com/article/10.1007/s10198-014-0566-8)

[**Fischer KE**, Stollenwerk B, Rogowski WH. Link between Process and Appraisal in Coverage Decisions An Analysis with Structural Equation Modeling. Med Decis Making. 2013 Nov 1;33(8):1009–25.](http://mdm.sagepub.com/content/33/8/1009)

[**Fischer KE**, Rogowski WH, Leidl R, Stollenwerk B. Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy. 2013 Oct;112(3):187–96.](http://www.sciencedirect.com/science/article/pii/S0168851013001085)

[**Fischer KE**. Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. BMC Medical Informatics and Decision Making. 2012 Aug 2;12(1):83.](http://www.biomedcentral.com/1472-6947/12/83/abstract)

[**Fischer KE**. A systematic review of coverage decision-making on health technologies—Evidence from the real world. Health Policy. 2012;107(2–3):218–30.](http://www.sciencedirect.com/science/article/pii/S0168851012001911)

[**Fischer KE**, Leidl R, Rogowski WH. A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention. Health Policy. 2011 Aug;101(3):290–9.](http://www.sciencedirect.com/science/article/pii/S0168851011000480)

[**Fischer KE**, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. International Journal of Technology Assessment in Health Care. 2011;27(04):313–21.](https://doi.org/10.1017/S0266462311000468) 

## Book chapters

Blankart K. Heilung um jeden Preis? - Die 20.000€ Pille oder die Herausforderung der Preissetzungsstrategie im Gesundheitswesen. In: Ritz A, Sager F, Lienhard A, editors. Fälle zu Public Management und Verwaltungswissenschaft. (forthcoming)

Blankart K. Der strategische Kampf: Wettbewerbsfähigkeit durch die europäische Waren- und Dienstleistungsfreiheit. In: Ritz A, Sager F, Lienhard A, Blankart CRB, editors. Fälle zu Public Management und Verwaltungswissenschaft. (forthcoming)


## Articles in German

[Kurte MS, Blankart K. Ambulant-sensitive Krankenhausfälle in Deutschland – Abgrenzung, Prävalenz und Kosten. Gesundh ökon Qual manag. 2019 May 7;24(06):277–91.](http://www.thieme-connect.de/DOI/DOI?10.1055/a-0890-9600)

Fischer K. Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. RPG Recht und Politik im Gesundheitswesen. 2013;19(3):67–81. 



